Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) PE Ratio: 149.47 (As of Jul. 20, 2026) — 17% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IST:ONCSM Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS IST:ONCSM
78 GF Score
Price ₺284.00
GF Value ₺255.12
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Oncosem Onkolojik Sistemlernayi ve Ticaret AS PE Ratio?

Oncosem Onkolojik Sistemlernayi ve Ticaret AS IST:ONCSM -1.13% 78 PE Ratio is 149.47 as of Jul. 20, 2026, which is 17% below its 10-year median of 179.87. GuruFocus rates IST:ONCSM with a GF Score™ of 78/100 and a GF Value™ of ₺255.12 (Modestly Overvalued). The stock has 4 warning signs investors should review.

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-20), Oncosem Onkolojik Sistemlernayi ve Ticaret AS's share price is ₺284.00. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₺1.90. Therefore, Oncosem Onkolojik Sistemlernayi ve Ticaret AS's PE Ratio for today is 149.47.

During the past 7 years, Oncosem Onkolojik Sistemlernayi ve Ticaret AS's highest PE Ratio was 458.40. The lowest was 114.29. And the median was 179.87.

Oncosem Onkolojik Sistemlernayi ve Ticaret AS's EPS (Diluted) for the three months ended in Mar. 2026 was ₺0.20. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₺1.90.

As of today (2026-07-20), Oncosem Onkolojik Sistemlernayi ve Ticaret AS's share price is ₺284.00. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was ₺2.03. Therefore, Oncosem Onkolojik Sistemlernayi ve Ticaret AS's PE Ratio without NRI ratio for today is 140.25.

During the past 7 years, Oncosem Onkolojik Sistemlernayi ve Ticaret AS's highest PE Ratio without NRI was 354.58. The lowest was 107.14. And the median was 146.70.

Oncosem Onkolojik Sistemlernayi ve Ticaret AS's EPS without NRI for the three months ended in Mar. 2026 was ₺0.23. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was ₺2.03.

Oncosem Onkolojik Sistemlernayi ve Ticaret AS's EPS (Basic) for the three months ended in Mar. 2026 was ₺0.20. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was ₺1.90.

Back to Basics: PE Ratio


Oncosem Onkolojik Sistemlernayi ve Ticaret AS  (IST:ONCSM) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Oncosem Onkolojik Sistemlernayi ve Ticaret AS PE Ratio Related Terms


Oncosem Onkolojik Sistemlernayi ve Ticaret AS PE Ratio Historical Data

* Premium members only.

The historical data trend for Oncosem Onkolojik Sistemlernayi ve Ticaret AS's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncosem Onkolojik Sistemlernayi ve Ticaret AS PE Ratio Chart

Oncosem Onkolojik Sistemlernayi ve Ticaret AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio
Get a 7-Day Free Trial N/A N/A At Loss At Loss 125.24

Oncosem Onkolojik Sistemlernayi ve Ticaret AS Quarterly Data
Dec19 Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss 192.71 178.56 125.24 132.89

IST:ONCSM vs ABT, SYK, MDT: PE Ratio Comparison

For the Medical Devices subindustry, Oncosem Onkolojik Sistemlernayi ve Ticaret AS's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncosem Onkolojik Sistemlernayi ve Ticaret AS PE Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Oncosem Onkolojik Sistemlernayi ve Ticaret AS's PE Ratio distribution charts can be found below:

* The bar in red indicates where Oncosem Onkolojik Sistemlernayi ve Ticaret AS's PE Ratio falls into.


IST:ONCSM
78GF Score
Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS IST:ONCSM
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncosem Onkolojik Sistemlernayi ve Ticaret AS PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Oncosem Onkolojik Sistemlernayi ve Ticaret AS's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=284.00/1.900
=149.47

Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Share Price of today is ₺284.00.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺1.90.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio →
What does a PE Ratio of 149.47 mean?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) has a PE Ratio of 149.47 as of Jul. 20, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Oncosem Onkolojik Sistemlernayi ve Ticaret AS and its competitors. This is 17% below median its historical median of 179.87. Over the past decade, Oncosem Onkolojik Sistemlernayi ve Ticaret AS's PE Ratio has ranged from 114.29 to 458.40.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS's PE Ratio too high?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current PE Ratio of 149.47 is 17% below median its 10-year median of 179.87. Over the past 10 years, this metric has ranged from a low of 114.29 to a high of 458.40. Overall, Oncosem Onkolojik Sistemlernayi ve Ticaret AS has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncosem Onkolojik Sistemlernayi ve Ticaret AS's PE Ratio compare to ABT and SYK?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's PE Ratio of 149.47 can be compared against companies in the Medical Devices & Instruments industry. Historically, Oncosem Onkolojik Sistemlernayi ve Ticaret AS's own PE Ratio has ranged from 114.29 to 458.40 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for a Medical Devices & Instruments company?
A good PE Ratio depends on the Medical Devices & Instruments industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Oncosem Onkolojik Sistemlernayi ve Ticaret AS and its competitors. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current PE Ratio is 149.47, which is 17% below median its own 10-year median of 179.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) is currently considered Modestly Overvalued. The stock's GF Value™ is ₺255.12, compared to a current price of ₺284.00 — trading 11.3% above its estimated fair value. The current PE Ratio is 149.47, which is 17% below median its 10-year median of 179.87. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM), the current PE Ratio is 149.47 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) Overvalued in 2026?

Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock appears to be overvalued. The current stock price of ₺284.00 is trading 11.3% above its estimated GF Value™ of ₺255.12. GuruFocus considers Oncosem Onkolojik Sistemlernayi ve Ticaret AS to be Modestly Overvalued.

Key valuation signals for IST:ONCSM:

  • PE Ratio: 149.47 (17% below median its 10-year median of 179.87)
  • GF Value™: ₺255.12 vs. price of ₺284.00 (11.3% above fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the IST:ONCSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Oncosem Onkolojik Sistemlernayi ve Ticaret AS Business Description

Address Mutlukent Mah. 1988 Cad. No: 12, Cankaya, Ankara, TUR
Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS is specialized in the production of equipment and medical devices used in cancer treatment.
78GF Score

Get the complete analysis for IST:ONCSM

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₺284.00
Price
₺255.12
GF Value